Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) EPS (Weighted Average and Diluted) (2021 - 2025)

Terns Pharmaceuticals filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.24 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 4.35% to -$0.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.03 through Dec 2025, up 8.04% year-over-year, with the annual reading at -$1.03 for FY2025, 8.04% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.24 in Q4 2025 for Terns Pharmaceuticals, up from -$0.27 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.57 in Q4 2021 and bottomed at -$0.55 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.23, with a median of -$0.29 recorded in 2023.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 110.85% in 2022 before it soared 54.55% in 2023.
  • Terns Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $1.57 in 2021, then plummeted by 110.85% to -$0.17 in 2022, then crashed by 70.59% to -$0.29 in 2023, then grew by 20.69% to -$0.23 in 2024, then decreased by 4.35% to -$0.24 in 2025.
  • Per Business Quant, the three most recent readings for TERN's EPS (Weighted Average and Diluted) are -$0.24 (Q4 2025), -$0.27 (Q3 2025), and -$0.26 (Q2 2025).